Main content

    Prostate Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Metastatic Prostate Cancer  |  Non-Metastatic Prostate Cancer


    Active Trials

    Metastatic Prostate Cancer

    Title: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
    Description: This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with prostate cancer that has spread to other parts of the body
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects, 18 y/o and older, with metastatic adenocarcinoma of the prostate
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study NRG-BR001

    Title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
    Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of metastatic prostate cancer
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study S1216

    Back to top

    Non-Metastatic Prostate Cancer

    Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
    Description: The purpose of this study is to determine if JNJ-56021927 plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older who are indicated and planned to receive primary radiation therapy for prostate cancer
    Status: Coming soon
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Janssen PCR3003

    Title: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
    Description: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0924

    • updated August 2016

    Back to top